My Medical Gateway Blog

Facing long NHS waiting lists and high private treatment costs in the UK, many patients are now exploring faster, more affordable options abroad. With NHS delays affecting millions and private surgery often costing £15,000 or more, accessing high-quality care in Europe is becoming an increasingly practical solution. Patients can benefit from shorter waiting times, transparent pricing and comprehensive treatment packages – without compromising on clinical standards. For those seeking timely and cost-effective care, treatment abroad is no longer a last resort.

On 13 March 2025, Wes Streeting announced plans to abolish NHS England, arguing that the system had become too bureaucratic and needed fewer “checkers” and more “doers”.  More than a year later, the data suggests the opposite is happening. 

According to The Daily Telegraph on 28 April 2026, NHS England has advertised 1,214 roles since that announcement, including 577 non-medical positions, while its monthly wage bill has increased by £3 million. This is taking place at the same time as NHS waiting lists remain at record levels. Officially, there are 7.2 million cases on NHS England waiting lists, but the true number is likely to be closer to 9 million. More than 300,000 patients have been waiting over a year for treatment, around 1.6 million are waiting more than six weeks for diagnostic tests such as MRI and CT scans, and A&E performance continues to fall well below the 95 per cent target. For patients, the reality is straightforward: waiting times are still too long, and access to treatment remains uncertain.

The NHS is often described as having an efficiency problem, but the evidence points to something more fundamental. Demand for healthcare continues to rise, driven by an ageing population and increasing levels of chronic disease. At the same time, the cost of delivering care is rising sharply. Spending on medicines alone now exceeds £20 billion per year in England, with advanced treatments such as cancer drugs and biologics increasing costs by 5–7 per cent annually. The cost of medical technology is also rising. A modern MRI scanner can cost between £1 million and £2 million, while robotic surgical systems can exceed £2 million, with ongoing per-procedure costs. 

These are not optional upgrades but part of the standard of modern care. Yet the UK still has fewer MRI and CT scanners per capita than most comparable European countries, and hospital infrastructure is ageing after years of underinvestment. Independent estimates suggest a capital backlog of £10 billion or more simply to bring the NHS estate up to a modern standard.

This creates a structural squeeze. Demand is rising, the cost of care is rising, and the system does not have the physical capacity – machines, theatres and equipment – to keep up. Against that backdrop, the continued expansion of administrative roles becomes more than a question of efficiency. It becomes a question of priorities. Additional layers of management may improve oversight, reporting and governance, but they do not increase the number of operations performed, reduce diagnostic delays or shorten waiting lists. 

The NHS is attempting to solve a delivery problem through organisational reform while absorbing rising input costs that require greater capital investment. That is the contradiction at the heart of the system.

For many patients, the next step is to consider private healthcare in the UK. But this brings a second constraint: cost. Private treatment prices in the UK are high, particularly in London. A knee replacement typically costs between £15,000 and £20,000 or more, a hip replacement between £14,000 and £18,000, and ACL surgery between £8,000 and £10,000. These prices reflect the same underlying pressures seen in the NHS, including high operating costs, limited capacity and expensive infrastructure. Private healthcare may offer faster access, but it is not always affordable.

What many patients do not initially realise is that there is another option. Across Europe, private healthcare systems operate with greater capacity, more competition and lower cost bases. This allows hospitals to offer high-quality treatment at significantly lower prices while maintaining clinical standards. In many cases, procedures such as knee and hip replacements are 30 to 50 per cent cheaper than in the UK, with treatment packages that include surgery, hospital stay and post-operative care. The difference is structural rather than promotional. It reflects how those healthcare systems are organised and funded.

The pattern that is now emerging is clear. NHS waiting lists remain structurally high, the cost of modern healthcare continues to rise, and UK private treatment remains expensive. These factors are not temporary. They are the result of long-term trends in demand, cost and capacity. Even if the NHS improves coordination and efficiency, it cannot eliminate the gap between demand and supply without significant investment in infrastructure and clinical delivery. At the same time, rising costs for medicines, machines and technology make it increasingly difficult for both the NHS and UK private providers to reduce prices.

For patients, this creates a practical decision. They are looking for speed, certainty, affordability and quality, but that combination is increasingly difficult to find within the UK alone. Accessing treatment abroad is no longer unusual or niche. It is becoming a rational response to the realities of the system. The NHS is trying to reform itself, but reform does not create capacity overnight. Until the underlying constraints are addressed, waiting times will remain long and private treatment will remain expensive. For patients who cannot afford to wait and cannot justify UK private prices, the solution may already exist. It simply lies beyond the UK.